摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Amino-3-methoxy-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidine | 111375-24-7

中文名称
——
中文别名
——
英文名称
4-Amino-3-methoxy-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidine
英文别名
(2R,3R,4S,5R)-2-(4-amino-3-methoxy-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol;4-Amino-3-methoxy-1-beta-d-ribofuranosylpyrazolo[3,4-d]pyrimidine;(2R,3R,4S,5R)-2-(4-amino-3-methoxypyrazolo[3,4-d]pyrimidin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol
4-Amino-3-methoxy-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidine化学式
CAS
111375-24-7
化学式
C11H15N5O5
mdl
——
分子量
297.271
InChiKey
IHHUDODCEUORJK-RPKMEZRRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.5
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    149
  • 氢给体数:
    4
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-Amino-3-methoxy-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidine溶剂黄146 、 sodium nitrite 作用下, 以19%的产率得到3-Methoxy-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidin-4(5H)-one
    参考文献:
    名称:
    某些与腺苷,肌苷和鸟苷相关的3-烷氧基-1-β-D-呋喃呋喃糖基吡唑并[3,4- d ]嘧啶的合成†
    摘要:
    在结构上与腺苷,肌苷和鸟苷相关的几种3-烷氧基取代的吡唑并[3,4- d ]嘧啶核糖核苷已经通过预先形成的含有3-烷氧基取代基的糖苷配基前体的直接糖基化作用而制备。5(3)-氨基-3(5)-乙氧基吡唑-4-羧酰胺(6b)与甲酰胺或乙基黄原酸钾的闭环得到3-乙氧基铝嘌呤醇(7b)和3-乙氧基-6-thioxopyrazolo [3,4- d ]-嘧啶-4(5 H,7 H)-一(10)。10的甲基化得到相应的6-甲硫基衍生物15。5(3)-甲氧基吡唑-4-羧酰胺(6a)与甲酰胺一起得到3-甲氧基铝嘌呤醇(7a)。用乙酸甲form提供的4-氨基-3-甲氧基吡唑并[3,4- d ]嘧啶(4)处理5(3)-氨基-3(5)-甲氧基吡唑-4-腈(5a)。在三氟化硼醚化物的存在下,7b与1 - O-乙酰基-2,3,5-三-O-苯甲酰基-D-呋喃呋喃糖进行高温糖基化反应,得到N-1和N-2糖基的2:1混合物
    DOI:
    10.1002/jhet.5570230651
  • 作为产物:
    参考文献:
    名称:
    某些与腺苷,肌苷和鸟苷相关的3-烷氧基-1-β-D-呋喃呋喃糖基吡唑并[3,4- d ]嘧啶的合成†
    摘要:
    在结构上与腺苷,肌苷和鸟苷相关的几种3-烷氧基取代的吡唑并[3,4- d ]嘧啶核糖核苷已经通过预先形成的含有3-烷氧基取代基的糖苷配基前体的直接糖基化作用而制备。5(3)-氨基-3(5)-乙氧基吡唑-4-羧酰胺(6b)与甲酰胺或乙基黄原酸钾的闭环得到3-乙氧基铝嘌呤醇(7b)和3-乙氧基-6-thioxopyrazolo [3,4- d ]-嘧啶-4(5 H,7 H)-一(10)。10的甲基化得到相应的6-甲硫基衍生物15。5(3)-甲氧基吡唑-4-羧酰胺(6a)与甲酰胺一起得到3-甲氧基铝嘌呤醇(7a)。用乙酸甲form提供的4-氨基-3-甲氧基吡唑并[3,4- d ]嘧啶(4)处理5(3)-氨基-3(5)-甲氧基吡唑-4-腈(5a)。在三氟化硼醚化物的存在下,7b与1 - O-乙酰基-2,3,5-三-O-苯甲酰基-D-呋喃呋喃糖进行高温糖基化反应,得到N-1和N-2糖基的2:1混合物
    DOI:
    10.1002/jhet.5570230651
点击查看最新优质反应信息

文献信息

  • [EN] ATG7 INHIBITORS AND THE USES THEREOF<br/>[FR] INHIBITEURS D'ATG7 ET LEURS UTILISATIONS
    申请人:MILLENNIUM PHARM INC
    公开号:WO2018089786A1
    公开(公告)日:2018-05-17
    Disclosed are chemical entities which are compounds of formula (I) : or a pharmaceutically acceptable salt thereof, wherein R1, R2, and Ra have the values described herein. Chemical entities according to the disclosure can be useful as inhibitors of ATG7. Further provided are pharmaceutical compositions comprising a chemical entity of the disclosure and methods of using the compositions in the treatment of cancer.
    本公开涉及化学实体,其为以下式(I)的化合物:或其药学上可接受的盐,其中R1、R2和Ra具有此处描述的值。根据本公开的化学实体可以用作ATG7的抑制剂。还提供了包括本公开的化学实体的药物组合物以及使用这些组合物治疗癌症的方法。
  • ATG7 inhibitors and the uses thereof
    申请人:Millennium Pharmaceuticals, Inc.
    公开号:US10865208B2
    公开(公告)日:2020-12-15
    Disclosed are chemical entities which are compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, and Ra have the values described herein. Chemical entities according to the disclosure can be useful as inhibitors of ATG7. Further provided are pharmaceutical compositions comprising a chemical entity of the disclosure and methods of using the compositions in the treatment of cancer.
    所公开的化学实体为式(I)化合物:或其药学上可接受的盐,其中 R1、R2 和 Ra 具有本文所述的值。根据本公开的化学实体可用作 ATG7 的抑制剂。进一步提供了包含本公开的化学实体的药物组合物,以及使用该组合物治疗癌症的方法。
  • Synthesis of certain 3-alkoxy-1-β-D-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidines structurally related to adenosine, inosine and guanosine
    作者:Jack D. Anderson、N. Kent Dalley、Ganapathi R. Revankar、Roland K. Robins
    DOI:10.1002/jhet.5570230651
    日期:1986.11
    Several 3-alkoxysubstituted pyrazolo[3,4-d]pyrimidine ribonucleosides structurally related to adenosine, inosine and guanosine have been prepared by the direct glycosylation of preformed aglycon precursor containing a 3-alkoxy substituent. Ring closure of 5(3)-amino-3(5)-ethoxypyrazole-4-carboxamide (6b) with either formamide or potassium ethyl xanthate gave 3-ethoxyallopurinol (7b) and 3-ethoxy-6-thioxopyrazolo[3
    在结构上与腺苷,肌苷和鸟苷相关的几种3-烷氧基取代的吡唑并[3,4- d ]嘧啶核糖核苷已经通过预先形成的含有3-烷氧基取代基的糖苷配基前体的直接糖基化作用而制备。5(3)-氨基-3(5)-乙氧基吡唑-4-羧酰胺(6b)与甲酰胺或乙基黄原酸钾的闭环得到3-乙氧基铝嘌呤醇(7b)和3-乙氧基-6-thioxopyrazolo [3,4- d ]-嘧啶-4(5 H,7 H)-一(10)。10的甲基化得到相应的6-甲硫基衍生物15。5(3)-甲氧基吡唑-4-羧酰胺(6a)与甲酰胺一起得到3-甲氧基铝嘌呤醇(7a)。用乙酸甲form提供的4-氨基-3-甲氧基吡唑并[3,4- d ]嘧啶(4)处理5(3)-氨基-3(5)-甲氧基吡唑-4-腈(5a)。在三氟化硼醚化物的存在下,7b与1 - O-乙酰基-2,3,5-三-O-苯甲酰基-D-呋喃呋喃糖进行高温糖基化反应,得到N-1和N-2糖基的2:1混合物
查看更多

同类化合物

别嘌呤醇核糖苷 [3,4-二乙酰氧基-5-(5-甲硫基-2,4,8,9-四氮杂双环[4.3.0]壬-2,4,7,10-四烯-9-基)四氢呋喃-2-基]甲基乙酸酯 4-氨基-3-苄基-1H-吡唑并[3,4-d]嘧啶-1-β-D-呋喃核糖 1 beta-呋喃核糖基-4-(甲硫基)吡唑并(3,4-d)嘧啶 4-amino-3-bromo-6-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine 4-amino-3-bromo-5-methyl-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine-6-one 8-aza-7-deaza-7-propynyladenosine 1-(β-D-ribofuranosyl)-4,6-bis(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine 1-(β-D-ribofuranosyl)-3-carboxy-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine 4-amino-1-(α-D-arabinofuranosyl)pyrazolo<3,4-d>pyrimidine 2-(5-Amino-4-iminopyrazolo[3,4-d]pyrimidin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol;hydrochloride 1-(β-D-ribofuranosyl)-3-thiocarbamoyl-4-amino-6-methylmercaptopyrazolo<3,4-d>pyrimidine 1-(β-D-ribofuranosyl)-4-amino-6-methylmercaptopyrazolo<3,4-d>pyrimidine-3-carboxamidine 1-(β-D-ribofuranosyl)-3-thiocarbamoyl-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine 1-(β-D-ribofuranosyl)-3-cyano-4-(N-piperidino)-6-methylmercaptopyrazolo<3,4-d>pyrimidine 1-(β-D-ribofuranosyl)-3-cyano-4-(N-morpholino)-6-methylmercaptopyrazolo<3,4-d>pyrimidine methyl 1-(β-D-ribofuranosyl)-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine-3-imidocarboxylate 1-(β-D-ribofuranosyl)-3-cyanomethyl-4-(N-morpholino)-6-methylmercaptopyrazolo<3,4-d>pyrimidine methyl 1-(β-D-ribofuranosyl)-4-methoxy-6-methylmercaptopyrazolo<3,4-d>pyrimidine-3-imidocarboxylate 1-(β-D-ribofuranosyl)-3-cyanomethyl-4-amino-6-methylmercaptopyrazolo<3,4-d>pyrimidine methyl 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran- 2-yl]-1H-pyrazolo[3,4-d]pyrimidine-3-carboximidoate 4-amino-1-(2,3,5-tri-O-benzyl-α-D-arabinofuranosyl)pyrazolo<3,4-d>pyrimidine 4-Amino-3-methoxy-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidine 4-amino-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidine-3-carbonitrile 4-amino-1-(β-D-ribofuranosyl)-3-[2-(methoxycarbonyl)ethenyl]-1H-pyrazolo[3,4-d]pyrimidine 1-Pentofuranosyl-1h-pyrazolo[3,4-d]pyrimidin-4-amine 4-Amino-1-pentofuranosyl-1h-pyrazolo[3,4-d]pyrimidine-3-carbonitrile 4-Amino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrazolo[3,4-d]pyrimidine-3-carboximidamide Methyl 4-amino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrazolo[3,4-d]pyrimidine-3-carboximidate 1H-Pyrazolo[3, 4-amino-1-beta-D-ribofuranosyl-, hydrazide, hemihydrate 2-(Hydroxymethyl)-5-[4-(methylamino)pyrazolo[3,4-d]pyrimidin-1-yl]oxolane-3,4-diol [3,4-Diacetyloxy-5-(4-chloropyrazolo[3,4-d]pyrimidin-1-yl)oxolan-2-yl]methyl acetate 1-beta-D-ribofuranosyl-4-methoxypyrazolo[3,4-d] pyrimidine 2-[4-(Dimethylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol 4-{[(4-Nitrophenyl)methyl]sulfanyl}-1-pentofuranosyl-1H-pyrazolo[3,4-d]pyrimidine 2-(4-Hydrazinylpyrazolo[3,4-d]pyrimidin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol [5-[4-(Benzylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl acetate 2-(Hydroxymethyl)-5-(4-prop-2-enylsulfanylpyrazolo[3,4-d]pyrimidin-1-yl)oxolane-3,4-diol N-Benzyl-1-pentofuranosyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 2-(Hydroxymethyl)-5-pyrazolo[3,4-d]pyrimidin-1-yloxolane-3,4-diol [5-[4-(Furan-2-ylmethylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl acetate [3,4-Diacetyloxy-5-(4-anilinopyrazolo[3,4-d]pyrimidin-1-yl)oxolan-2-yl]methyl acetate 1-Pentofuranosyl-N-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine [3,4-Diacetyloxy-5-[4-(3-methyl-5-nitroimidazol-4-yl)sulfanylpyrazolo[3,4-d]pyrimidin-1-yl]oxolan-2-yl]methyl acetate 2-[4-(Furan-2-ylmethylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol 2-[4-(Hydroxyamino)pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol 2-(Hydroxymethyl)-5-[4-(3-methyl-5-nitroimidazol-4-yl)sulfanylpyrazolo[3,4-d]pyrimidin-1-yl]oxolane-3,4-diol [3,4-Diacetyloxy-5-[4-(aziridin-1-yl)pyrazolo[3,4-d]pyrimidin-1-yl]oxolan-2-yl]methyl acetate 1-(β-D-ribofuranosyl)-4,6-bis(chlorodifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine 1-(β-D-ribofuranosyl)-4,6-bis(difluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine